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ABSTRACT 
Background: Ischemic heart disease is a major cause of death globally. Rupture of a coronary atherosclerotic 
plaque with occluding thrombus formation is the main cause of myocardial ischemia and infarction.  A healthy 
vascular endothelium is pivotal for maintenance of vessel patency and normal blood flow, which is important 
for prevention of thrombotic events. In the event of an intra-arterial thrombosis formation the endothelium 
reacts with vasodilation and activation of the endogenous fibrinolytic system. Endothelial dysfunction (ED) is 
a common denominator in patients with different cardiovascular risk factors including hypertension. ED 
promotes a vasoconstrictive, prothrombotic, and  proinflammatory state.  ED in hypertension is associated with 
impaired endothelium-dependent vasodilation (EDV) and impaired endogenous fibrinolysis measured as acute 
stimulated t-PA (tissue plasminogen activator) release. Hypertension confers a prothrombotic state and ED 
could be an important contributor to the increased risk for atherothrombotic events. 
Aims: The overall aim of this thesis was to pharmacologically improve endothelial function in hypertension 
and normotension, and to investigate the long-term prognostic impact of hypertension. The aim of Study I-II 
was to investigate if pharmacological intervention by atorvastatin (ATV) or sodium nitroprusside (SNP) may 
improve vascular function in terms of EDV or fibrinolytic capacity, respectively, in hypertensive men. The aim 
of Study III was to evaluate if histone deacetylase inhibition by valproic acid (VPA) affects the endogenous 
fibrinolytic system, measured as t-PA release capacity or plasminogen activator inhibitor-1 (PAI-I) levels in a 
cohort of healthy men. The aim of Study IV was to investigate the long-term prognostic impact of hypertension 
on the mortality after percutaneous coronary intervention (PCI). 
Methods: In the clinical experimental studies, venous occlusion plethysmography and intra-brachial infusion of 
vasoactive substances were used to assess endothelium-dependent vasodilation (EDV), and endothelium-
independent vasodilation (EIDV) or vasoconstriction responses in the forearm (Studies I-III). The perfused 
forearm model was used to measure stimulated t-PA release capacity (Studies II-III) in the forearm. t-PA 
Release was stimulated by intra-brachial infusion of Substance P. Long-term prognostic impact of 
hypertension on total mortality after PCI was investigated in a large register study using the Swedish Coronary 
Angiography and Angioplasty Register (SCAAR), in which data were analyzed for 175.892 patients. 
Results: ATV treatment did not improve EDV acutely in hypertensive men. Forearm vascular resistance in 
response to SNP was lowered by ATV, and vasoconstriction in response to Angiotensin II (Ang II) was 
diminished by ATV treatment. Acute blood pressure lowering by SNP did not affect Substance P induced t-PA 
release capacity in patients with hypertension. VPA treatment resulted in considerably decreased levels of 
circulating PAI-1 antigen, and the t-PA:PAI-1 antigen ratio increased. Acute t-PA release in response to 
Substance P was not affected by VPA. The SCAAR-study showed that hypertension is associated with higher 
mortality risk in patients undergoing PCI in Sweden, and the risk was highest in patients less than 65 years, in 
smokers and in patients with ST-elevation myocardial infarction (STEMI).  
Conclusions: The observed acute statin effects in hypertension seem to be endothelium-independent and 
related to vascular smooth muscle cell function. Acute blood pressure lowering does not restore the impaired 
fibrinolytic capacity in hypertension, suggesting a diminished releasable t-PA pool in the endothelium. 
Intervention by VPA treatment did not affect the acute stimulated t-PA release capacity in healthy man. In 
contrary, VPA diminished plasma PAI-1 antigen levels and altered the fibrinolytic balance, measured as t-
PA:PAI-1 ratio in a profibrinolytic direction. Further studies are needed to confirm fibrinolytic effects of 
histone deacetylase inhibitors in patients with ED, e.g. established atherosclerosis. A long-term adverse impact 
of hypertension diagnosis on survival after PCI was demonstrated in a large-scale register study, and the 
highest risk was found in patients with STEMI. These findings underscore the importance of optimal 
secondary prevention including blood pressure control in patients with coronary artery disease. 
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